Amino Nitrogen And A Ring Bonded Directly To The Same Ring And Any Other Amino Nitrogen In The Compound Is Bonded Directly To One Of The Rings Patents (Class 514/647)
  • Patent number: 10745343
    Abstract: Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized. Uses of the various polymorphic forms of RAD1901-2HCl for cancer treatment are also disclosed.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: August 18, 2020
    Assignee: RADIUS PHARMACEUTICALS, INC.
    Inventors: Michael Paul Cruskie, Jr., Joshua Kyle Bolger, Jonathan Blake McKenzie, Pratik Sheth, Richard Edwards, Alex Eberlin, Michael Markey
  • Patent number: 10716950
    Abstract: A method for treating conditions associated with thalamocortical dysrhythmia. The method includes applying transcranial low voltage electrical stimulation (TLVES) therapy or transcranial magnetic stimulation (TMS) therapy to a patient in need thereof, and administering to the patient a dissociative anesthetic during the TLVES therapy or the TMS therapy. A number of conditions including tinnitus, depression and pain can be treated with TLVES or TMS in combination with the dissociative anesthetic, such as an NMADR inhibitor, including ketamine.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: July 21, 2020
    Inventor: Steven Richard Devore Best
  • Patent number: 10696647
    Abstract: The present invention relates to a compound of the following formula (I): or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of obsessions and/or compulsions in an individual.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: June 30, 2020
    Assignee: BIOCODEX
    Inventors: Marc Verleye, Marie-Emmanuelle Le Guern
  • Patent number: 10555917
    Abstract: Provided are methods of treating a neurological or psychiatric disorder in a subject in need thereof, comprising: administering to the subject a therapeutically effective amount of ketamine or a pharmaceutically acceptable salt thereof in combination with an amount of one or more compounds effective to increase the level of nicotinamide adenine dinucleotide (NAD+) in the subject.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: February 11, 2020
    Assignee: BNIW Ventures LLC.
    Inventors: Guriqbal S. Nandra, Irvin M. Wiesman
  • Patent number: 10385008
    Abstract: Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized. Uses of the various polymorphic forms of RAD1901-2HCl for cancer treatment are also disclosed.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: August 20, 2019
    Assignee: Radius Pharmaceuticals, Inc.
    Inventors: Michael Paul Cruskie, Jr., Joshua Kyle Bolger, Jonathan Blake McKenzie, Pratik Sheth, Richard Edwards, Alex Eberlin, Michael Markey
  • Patent number: 10328036
    Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: June 25, 2019
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: Thomas Jerussi, Qun Kevin Fang, Mark G. Currie
  • Patent number: 10265280
    Abstract: Formulations for treating ocular surface diseases, such as dry eye disease, and related methods are disclosed. The formulations include ambroxol or a chemical derivative thereof (for example, ambroxol hydrochloride) dispersed in a carrier and may optionally include a biocompatible polymer to provide extended release properties.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: April 23, 2019
    Inventors: Mingwu Wang, Cindy A Wang
  • Patent number: 10201505
    Abstract: Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: February 12, 2019
    Assignee: CIMA LABS INC.
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Randal A. Seburg, Manuel A. Vega Zepeda
  • Patent number: 9913803
    Abstract: The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: March 13, 2018
    Assignee: Amorsa Therapeutics, Inc.
    Inventors: Alex Nivorozhkin, Nelson Landrau
  • Patent number: 9724315
    Abstract: The present embodiments relate to topically delivered medication (compounded) for treatment of pain, inflammation, muscle fatigue, spasms, and/or other ailments. A transdermal cream may provide the effective topical administration of multiple medications simultaneously. The transdermal cream may include a salt load of approximately 30% or greater. The transdermal cream may include a unique base composition such that the transdermal cream may be able to remain stable and avoid degradation for six months or more and capable of effective delivery of active ingredient concentrations exceeding approximately 40% or more of the total formulation weight. The active ingredients may include a nerve depressant, NSAID, muscle relaxant, opiate agonist, local anesthetic, NMDA receptor antagonist, and a tricyclic antidepressant. In one embodiment, the transdermal cream may comprise ketamine HCL, gabapentin, clonidine HCL and baclofen.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: August 8, 2017
    Assignee: CMPD Licensing, LLC
    Inventors: Jay Richard Ray, II, Charles D. Hodge
  • Patent number: 9630951
    Abstract: Compounds of formula I and a method for their preparation are described: where R1, R2 and R3 are the same or different and signify hydrogens, halogens, alkyl, nitro, amino, alkylcarbonylamino, alkylamino or dialkylamino group; R4 signifies -alkyl-aryl or -alkyl-heteroaryl; X signifies CH2, oxygen atom or sulphur atom; n is 2 or 3; including the individual (R)- and (S)-enantiomers or mixtures of enantiomers thereof; and including pharmaceutically acceptable salts and esters thereof. The compounds have potentially valuable pharmaceutical properties for the treatment of cardiovascular disorders such as hypertension and chronic heart failure.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: April 25, 2017
    Assignee: BIAL-PORTELA & CA, S.A.
    Inventors: Patricio Manuel Vieira Araujo Soares Da Silva, David Alexander Learmonth, Alexander Beliaev
  • Patent number: 9592207
    Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: March 14, 2017
    Assignees: Icahn School of Medicine at Mount Sinai, Yale University, The United States of America, as represented by The Secretary, Department of Health and Human Services
    Inventors: Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, John H. Krystal
  • Patent number: 9585850
    Abstract: The present invention is directed to a method of treating Parkinson's disease using arylcyclopropylamine compounds. The arylcyclopropylamine compounds have the following formula wherein R1, R2, R3, R4, R5 and R6 are described herein.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: March 7, 2017
    Assignee: Duke University
    Inventors: Dewey G. McCafferty, Julie A. Pollock, David M. Gooden, Marc G. Caron, Raul R. Gainetdinov, Tatyana D. Sotnikova
  • Patent number: 9463168
    Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: October 11, 2016
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), AURIS MEDICAL AG
    Inventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
  • Patent number: 9422229
    Abstract: The invention relates to protein binding interacting/binding compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating 5-HT2C disorders, including diseases and disorders mediated by GPCRs.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: August 23, 2016
    Assignee: University of Florida Research Foundation, Inc.
    Inventor: Raymond G. Booth
  • Patent number: 9260413
    Abstract: The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: February 16, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Scott Wolkenberg, Scott T. Harrison, James C. Barrow, Zhijan Zhao, Jeffrey Melamed, Nathan R. Kett, Amy Zartman
  • Patent number: 9102754
    Abstract: Compositions and methods are provided for modulating an immune response in a vertebrate subject. Compositions and methods can comprise administering a modified host defense peptide to the vertebrate subject in an amount effective to activate the immune response in the vertebrate subject, wherein the modified host defense peptide is inverted in amino acid sequence from an amino terminus to a carboxy terminus or modified to one or more D-amino acids, or both modifications, when compared to a host defense peptide. Compositions and methods are provided which comprise administering a modified host defense peptide to the vertebrate subject in an amount effective to modify an immune response in the vertebrate subject.
    Type: Grant
    Filed: June 27, 2008
    Date of Patent: August 11, 2015
    Assignee: University of Saskatchewan
    Inventors: Scott Kirk Napper, Kenneth Jason Kindrachuk, Samuel Kwadwo Attah-Poku
  • Patent number: 9072662
    Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: July 7, 2015
    Assignees: Auris Medical AG, Institut National De La Sante et de La Recherche Medicale
    Inventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
  • Patent number: 9061966
    Abstract: The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I) as described and defined herein, and their use in therapy, including, e.g., the treatment or prevention of cancer.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: June 23, 2015
    Assignee: ORYZON GENOMICS S.A.
    Inventors: Julio Castro-Palomino Laria, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Alberto Ortega Muñoz, Núrla Valls Vidal
  • Publication number: 20150148355
    Abstract: A silicone gel (“silogel”) composition used to deliver pharmaceutical products transdermally as well as a method for producing the silogel composition, which may contain up to 80% additive ingredients. Preferred embodiments of the invention may include silogel compositions which provide high viscosity/no separation due to API. They are not temperature-sensitive, have no shear stress from the ointment mill/EMP, have no gumming up/stickiness, and no hardening.
    Type: Application
    Filed: November 24, 2014
    Publication date: May 28, 2015
    Inventor: John Olin Trimble
  • Publication number: 20150118302
    Abstract: Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.
    Type: Application
    Filed: October 29, 2014
    Publication date: April 30, 2015
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
  • Publication number: 20150119396
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and theft use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
    Type: Application
    Filed: October 22, 2012
    Publication date: April 30, 2015
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Maria de los Angeles Estiarte Martínez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria
  • Publication number: 20150118301
    Abstract: Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a drug that is commonly susceptible to abuse.
    Type: Application
    Filed: September 4, 2014
    Publication date: April 30, 2015
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
  • Publication number: 20150118295
    Abstract: Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a drug that is commonly susceptible to abuse.
    Type: Application
    Filed: September 12, 2014
    Publication date: April 30, 2015
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
  • Publication number: 20150118300
    Abstract: Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a drug that is commonly susceptible to abuse.
    Type: Application
    Filed: July 17, 2014
    Publication date: April 30, 2015
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
  • Patent number: 9005637
    Abstract: Compositions and methods for combination therapy are provided. The compositions comprise a multiple unit dosage form having both a therapeutic agent and a nutritional supplement. The combination therapy is useful for restoring a nutrient depletion associated with a particular disease state. Additionally, the combination therapy can prevent or attenuate the depletion of a nutrient caused, in whole or in part, by the co-administrated therapeutic drug. Methods of manufacturing the formulations are likewise described.
    Type: Grant
    Filed: April 5, 2013
    Date of Patent: April 14, 2015
    Assignee: JDS Therapeutics, LLC
    Inventor: James R Komorowski
  • Patent number: 8987336
    Abstract: The present invention is a method for increasing serotonin activity in mammary glands such that involution of milk secretion of the same mammary glands occurs. The present invention further is a composition that can be implanted, or infused into the mammary glands to cause involution of milk secretion.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: March 24, 2015
    Assignee: Amelgo, LLC
    Inventors: Nelson D. Horseman, Robert J. Collier, Aaron M. Marshall, Laura Hernandez Baumgard
  • Publication number: 20150065487
    Abstract: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
    Type: Application
    Filed: November 11, 2014
    Publication date: March 5, 2015
    Inventors: Sara Hadida-Ruah, Anna Hazlewood, Peter Grootenhuis, Fred Van Goor, Ashvani Singh, Jinglan Zhou, Jason McCartney
  • Publication number: 20150056308
    Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).
    Type: Application
    Filed: June 17, 2014
    Publication date: February 26, 2015
    Inventors: Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, John H. Krystal
  • Publication number: 20150057360
    Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.
    Type: Application
    Filed: July 31, 2014
    Publication date: February 26, 2015
    Inventors: Matthieu GUITTON, Jean-Luc PUEL, Remy PUJOL, Jerome RUEL, Jing WANG
  • Patent number: 8957114
    Abstract: Provided herein are pharmaceutical compositions comprising transnorsertraline, salts and polymorphic forms of transnorsertraline, methods of making the compositions, and methods for their use for the treatment of CNS diseases, including depression.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: February 17, 2015
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Sharon M. Laughlin, Michael J. Sizensky, Surendra P. Singh, Harold Scott Wilkinson, Cai Gu Huang, Philip James Bonasia, Susan S. D'Souza
  • Patent number: 8916596
    Abstract: An embodiment of the invention provides preventing or treating a viral infection of a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor. Another embodiment of the invention provides preventing or treating reactivation of a virus after latency in a host, comprising administering to the host an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor. Another embodiment of the invention provides preventing or treating a viral infection in a mammal that has undergone, is undergoing, or will undergo an organ or tissue transplant, comprising administering to the mammal an effective amount of an inhibitor of the protein LSD1 and/or a monoamine oxidase inhibitor before, during, and/or after the organ or tissue transplant. The viral infection may be due to a herpesvirus, such as herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2), varicella zoster virus (VZV), or cytomegalovirus (CMV).
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: December 23, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Thomas Kristie, Yu Liang
  • Publication number: 20140364836
    Abstract: The present invention provides compositions containing (i) a pharmaceutically active agent selected from a group consisting of an arylcycloalkyamine of a derivative, analogue or pharmaceutically active salt thereof, and (ii) a biocompatible polymer or a combination of biocompatible polymers. The compositions or medicaments containing these compositions may be used for the prevention and/or treatment of inner ear diseases, e.g. tinnitus.
    Type: Application
    Filed: June 27, 2014
    Publication date: December 11, 2014
    Inventor: Thomas MEYER
  • Publication number: 20140357634
    Abstract: The invention relates to compounds that have an affinity to the ?-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.
    Type: Application
    Filed: August 14, 2014
    Publication date: December 4, 2014
    Applicant: GRÜNENTHAL GMBH
    Inventors: BERT NOLTE, WOLFGANG SCHRÖDER, KLAUS LINZ, WERNER ENGLBERGER, HANS SCHICK, HEINZ GRAUBAUM, BIRGIT ROLOFF, SIGRID OZEGOWSKI, JÓZSEF BÁLINT, HELMUT SONNENSCHEIN
  • Publication number: 20140343118
    Abstract: Described herein are methods of treating breast cancer using arylcyclopropylamine compounds.
    Type: Application
    Filed: March 14, 2014
    Publication date: November 20, 2014
    Inventors: Dewey G. McCafferty, Sunhee Hwang, Julie A. Pollock, David M. Gooden
  • Patent number: 8889743
    Abstract: The present invention discloses method to treat infections caused by filovirus. Such a method comprises blocking the PI3 kinase pathway or the calcium-associated pathway at the gene or protein level. Also disclosed herein are the compounds useful in the treatment of filoviral infection.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: November 18, 2014
    Assignee: Board of Regents, University of Texas System
    Inventors: Robert A. Davey, Andrey A. Kolokoltsov, Mohammad F. Saeed
  • Publication number: 20140329833
    Abstract: The invention relates to methods and compositions for the treatment or prevention of inflammation and inflammatory diseases or conditions. In particular, the invention relates to an LSD1 inhibitor, such as a 2-cyclylcylopropan-1-amine derivative, a phenelzine derivative and a propargylamine derivative, for use in treating or preventing inflammation and inflammatory diseases or conditions.
    Type: Application
    Filed: May 21, 2012
    Publication date: November 6, 2014
    Applicant: ORYZON GENOMICS, S.A
    Inventors: Tamara Maes, Marc Martinell Pedemonte, Julio Castro-Palomino Laria
  • Publication number: 20140324016
    Abstract: A method and apparatus for treatment of cardiac and renal diseases associated with the elevated sympathetic renal nerve activity by implanting a device to block the renal nerve signals to and from the kidney. The device can be a drug pump or a drug eluding implant for targeted delivery of a nerve-blocking agent to the periarterial space of the renal artery.
    Type: Application
    Filed: March 21, 2014
    Publication date: October 30, 2014
    Applicant: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Mark Gelfand, Howard R. Levin
  • Publication number: 20140309311
    Abstract: A pharmaceutical combination comprising as components (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and (b) at least one NMDA-antagonist, a pharmaceutical formulation and a dosage form comprising such a combination, and a method of treating pain, e.g. inflammatory pain or neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, with component (a) being administered either before or after component (b), and with components (a) or (b) being administered to the mammal either via the same pathway of administration or via different pathways of administration.
    Type: Application
    Filed: June 26, 2014
    Publication date: October 16, 2014
    Inventors: Klaus SCHIENE, Petra BLOMS-FUNKE
  • Publication number: 20140296241
    Abstract: The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite. (2R,6R)-hydroxynorketamine The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain disorder (CRPS) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.
    Type: Application
    Filed: October 15, 2012
    Publication date: October 2, 2014
    Inventors: Irving W. Wainer, Ruin Moaddel, Michel Bernier, Carlos A. Zarate, Marc C. Torjman, Michael E. Goldberg, Mary J. Tanga
  • Publication number: 20140296255
    Abstract: The invention relates to methods and compositions for the treatment or prevention of thrombosis, thrombus formation, a thrombotic event or complication, or a cardiovascular disease or event. In particular, the invention relates to an LSD inhibitor such as a 2-cyclylcyclopropan-1-amine derivative, a phenelzine derivative and a propargylamine derivative, for use in treating or preventing thrombosis, thrombus formation, a thrombotic event or complication, or a cardiovascular disease or event.
    Type: Application
    Filed: May 21, 2012
    Publication date: October 2, 2014
    Applicant: ORYZONG GENOMICS, S.A.
    Inventors: Tamara Maes, Marc Martinell Pedemonte
  • Patent number: 8846747
    Abstract: Provided are compounds which generally have a triketone structure. Examples of the compounds include derivatives of 1,3-cyclohexanedione, such as: 1,3-cyclohexanedione, 2-propanoyl-5-cyclohexyl-; 1,3-cyclohexanedione, 2-propanoyl-5-[4-fluorophenyl]-; 1,3-cyclohexanedione, 2-acetyl-5-[thien-2-yl]-; 1,3-cyclohexanedione, 2-acetyl-5-butyl-; and 1,3-cyclohexanedione, 2-propanoyl-5-[bicyclo[2.2.1]hept-2-en-5-yl]-. The compounds can be used to alter the lifespan of eukaryotic organisms and treat inflammation.
    Type: Grant
    Filed: November 17, 2010
    Date of Patent: September 30, 2014
    Assignees: University of Rochester, Southern Research Institute
    Inventors: David S. Goldfarb, Joseph A. Maddry, Lynn Rasmussen, Ellie Lucille White, Krister Wennerberg
  • Patent number: 8846720
    Abstract: The present invention provides a composition having an excellent controlling activity on a pest. The composition comprising a compound represented by Formula (1) and one or more diamide compound(s) selected from Group (A) shows an excellent controlling activity on a pest.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: September 30, 2014
    Assignee: Sumitomo Chemical Company, Limited
    Inventors: So Kiguchi, Soichi Tanaka
  • Patent number: 8846765
    Abstract: A pharmaceutical combination comprising as components (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and (b) at least one NMDA-antagonist, a pharmaceutical formulation and a dosage form comprising such a combination, and a method of treating pain, e.g. inflammatory pain or neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, with component (a) being administered either before or after component (b), and with components (a) or (b) being administered to the mammal either via the same pathway of administration or via different pathways of administration.
    Type: Grant
    Filed: June 14, 2011
    Date of Patent: September 30, 2014
    Assignee: Gruenenthal GmbH
    Inventors: Klaus Schiene, Petra Bloms-Funke
  • Publication number: 20140274981
    Abstract: The present invention is directed to an aqueous formulation of S-ketamine hydrochloride, preferably for nasal administration, wherein the formulation does not contain an antimicrobial preservative.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Esther D.G. Basstanie, Johanna Bentz, Roger C.A Embrechts, Nico Rudolph Niemeijer
  • Publication number: 20140275278
    Abstract: The present invention is directed to an aqueous formulation of S-ketamine hydrochloride, preferably for nasal administration, wherein the formulation does not contain an antimicrobial preservative.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Esther D.G. Basstanie, Johanna Bentz, Roger C.A Embrechts, Nico Rudolph Niemeijer
  • Publication number: 20140256742
    Abstract: The invention relates to methods and compositions for the treatment or prevention of Flaviviridae infections. In particular, the invention relates to an LSD1 inhibitor for use in treating or preventing Flaviviridae infections, including hepatitis C virus infections.
    Type: Application
    Filed: December 4, 2013
    Publication date: September 11, 2014
    Inventors: Jonathan A. BAKER, Matthew Collin Thor Fyfe
  • Publication number: 20140256729
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and theft use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
    Type: Application
    Filed: October 22, 2012
    Publication date: September 11, 2014
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Maria de los Ángeles Estiarte Martínez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria
  • Publication number: 20140256821
    Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).
    Type: Application
    Filed: March 5, 2014
    Publication date: September 11, 2014
    Applicants: Icahn School of Medicine at Mount Sinai, National Institute of Health, Yale University School of Medicine
    Inventors: Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, John H. Krystal
  • Publication number: 20140235591
    Abstract: Disclosed are compounds of Formula (I) and/or a salt thereof; wherein R is —OH or —OP(O)(OH)2. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Application
    Filed: February 20, 2014
    Publication date: August 21, 2014
    Inventors: T. G. Murali Dhar, Hai-Yun Xiao, Alaric J. Dyckman, Eric J. Chan, Marta Dabros, Daniel Richard Roberts